Amylin Pharmaceuticals (Nasdaq: AMLN) reports a Q3 loss of $0.30, ex-items, versus the consensus of a $0.45 loss ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE